Evidence map›Paper›PMID 25248709›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2014

[Application of target peptide in siRNA delivery 
for the research of lung cancer therapy].

Honglin Gao, Jianfeng Liu, Naling Song

Abstract readEnglish AbstractReview
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Honglin GaoDepartment of Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, 
Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300192, China.
Jianfeng LiuDepartment of Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, 
Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300192, China.
Naling SongDepartment of Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, 
Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300192, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is considered a kind of malignant tumors of the world highest incidence. As it is not sensitive to chemotherapy and easy to produce drug resistance, improving effect of anticancer drug becomes a research focus recent years. siRNA, small interfering RNA, can silence complemenary mRNA which is a kind of gene therapy. Target peptides are small molecular peptides which specifically bind to tumor surface materials. When used with siRNA, target peptides can increase accumulation of siRNA in tumor cells and enhance the silencing effect. As result, drug resistance of lung cancer reduced and the effect of therapy can be improved. This method provides new direction and strategy for targeted therapy of lung cancer. This article will make a brief overview of target peptides applying in siRNA dilivery for the research of lung cancer treatment.

Indexed as

Amino Acid SequenceDrug CarriersGenetic TherapyHumansLung NeoplasmsPeptidesRNA, Small InterferingDrug CarriersPeptidesRNA, Small Interfering

Identifiers

PMID25248709
PMCPMC6000512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.